See more : Banco Santander, S.A. (BNC.L) Income Statement Analysis – Financial Results
Complete financial analysis of Medesis Pharma S.A. (ALMDP.PA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Medesis Pharma S.A., a leading company in the Biotechnology industry within the Healthcare sector.
- Genetic Technologies Limited (GNTLF) Income Statement Analysis – Financial Results
- BBTV Holdings Inc. (BBTVF) Income Statement Analysis – Financial Results
- London Finance & Investment Group P.L.C. (LFI.L) Income Statement Analysis – Financial Results
- Bazel International Limited (BAZELINTER.BO) Income Statement Analysis – Financial Results
- SJVN Limited (SJVN.NS) Income Statement Analysis – Financial Results
Medesis Pharma S.A. (ALMDP.PA)
About Medesis Pharma S.A.
Medesis Pharma S.A., a clinical development stage biopharmaceutical company, engages in the development of orally administered molecule drug candidates to address unmet medical needs. Its products include NanoLithium (NP03), a clinical stage development product for the treatment of Alzheimer's disease; NanosiRNA DH for the treatment of Huntington's Disease; NU01 Plutonium and NU02 Cesium decorporation products for nuclear decorporation; a radioprotection drug to treat people irradiated following a civil or military nuclear accident (NP02 NanoManganese); NanosiRNA COVID-19, an antiviral treatment solution for viral diseases; and NanosiRNA Resistant cancers and NanosiRNA Oncolytic virus for the treatment of oncology. The company was founded in 2003 and is based in Montpellier, France.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 300.03K | 47.30K | 95.73K | 208.50K | 230.00K | 11.00K |
| Cost of Revenue | 2.96M | 2.25M | 2.27M | 705.69K | 370.00K | 364.00K |
| Gross Profit | -2.66M | -2.21M | -2.17M | -497.19K | -140.00K | -353.00K |
| Gross Profit Ratio | -888.16% | -4,662.24% | -2,267.22% | -238.46% | -60.87% | -3,209.09% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 2.25M | 678.85K | 364.00K | 359.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 1.24M | 1.02M | 2.25M | 678.85K | 364.00K | 359.00K |
| Other Expenses | 319.58K | 1.04M | -1.20M | -188.15K | 287.00K | 490.00K |
| Operating Expenses | 1.56M | 1.04M | 1.04M | 490.70K | 651.00K | 849.00K |
| Cost & Expenses | 4.53M | 3.29M | 3.31M | 1.20M | 1.02M | 1.21M |
| Interest Income | 94.46K | 73.85K | 12.03K | 8.63K | 13.09K | 0.00 |
| Interest Expense | 254.85K | 72.92K | 9.42K | 67.23K | 442.00K | 41.00K |
| Depreciation & Amortization | 295.99K | 101.60K | 155.17K | 92.91K | 166.88K | 366.00K |
| EBITDA | -3.84M | -3.05M | -3.05M | -894.98K | -622.00K | -835.00K |
| EBITDA Ratio | -1,281.48% | -6,486.92% | -3,183.59% | -425.11% | -270.43% | -7,590.91% |
| Operating Income | -4.23M | -3.24M | -3.21M | -987.89K | -789.00K | -1.20M |
| Operating Income Ratio | -1,409.62% | -6,857.87% | -3,358.25% | -473.81% | -343.04% | -10,918.18% |
| Total Other Income/Expenses | -166.38K | 15.03K | 2.60K | -2.62K | -442.00K | -41.00K |
| Income Before Tax | -4.40M | -3.24M | -3.21M | -1.05M | -1.23M | -1.24M |
| Income Before Tax Ratio | -1,465.07% | -6,855.90% | -3,355.53% | -501.91% | -535.22% | -11,290.91% |
| Income Tax Expense | -436.23K | -479.60K | -563.76K | -199.41K | -152.00K | -215.00K |
| Net Income | -3.96M | -2.76M | -2.65M | -847.08K | -1.08M | -1.02M |
| Net Income Ratio | -1,319.68% | -5,841.88% | -2,766.62% | -406.27% | -469.13% | -9,290.91% |
| EPS | -0.80 | -0.63 | -0.61 | -0.26 | -0.36 | -0.24 |
| EPS Diluted | -0.80 | -0.63 | -0.61 | -0.26 | -0.36 | -0.24 |
| Weighted Avg Shares Out | 4.96M | 4.39M | 4.37M | 3.27M | 3.00M | 4.22M |
| Weighted Avg Shares Out (Dil) | 4.96M | 4.39M | 4.37M | 3.27M | 3.00M | 4.22M |
Source: https://incomestatements.info
Category: Stock Reports